GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Barinthus Biotherapeutics
Barinthus (formerly Vaccitech) is the biotech company behind the technology used in the AstraZeneca COVID-19 vaccine. Its stock price reflects its efforts to apply its platform to vaccines against other infectious diseases and cancer.
Share prices of companies in the market segment - Pharma immune
Barinthus Biotherapeutics is a British biopharmaceutical company developing T-cell immunotherapy drugs for the treatment of chronic infectious diseases and cancer. We have classified it in the Pharma: Immunology category. The chart below shows the dynamics in this cutting-edge sector.
Broad Market Index - GURU.Markets
Barinthus Biotherapeutics is a British biopharmaceutical company developing T-cell immunotherapy drugs for the treatment of chronic infectious diseases and cancer. As a component of the GURU.Markets index, it represents the cutting-edge biotech sector. The chart below shows the US market. See how this company's stock compares to the US market.
Change in the price of a company, segment, and market as a whole per day
BRNS - Daily change in the company's share price Barinthus Biotherapeutics
Barinthus Biotherapeutics' daily share price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its vaccines and immunotherapy drugs.
Daily change in the price of a set of shares in a market segment - Pharma immune
Barinthus Biotherapeutics plc is a biotech company. This chart highlights the sector's extreme volatility. Comparison with BRNS, which focuses on vaccines and immunotherapy, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Barinthus Biotherapeutics is a biotech company focused on immunology. Its shares, like many in the sector, are highly volatile and react to news about clinical trials. These science-driven movements are part of the complex and diverse landscape of the entire stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Barinthus Biotherapeutics
Barinthus Biotherapeutics' year-to-date performance is the story of its T-cell vaccine platform. Its 12-month market cap depends entirely on clinical trial data for its hepatitis B and cancer drugs. Success could lead to a breakthrough in the treatment of these complex diseases.
Annual dynamics of market capitalization of the market segment - Pharma immune
Barinthus Biotherapeutics is a biotech company developing a new class of immunotherapy for the treatment of chronic infections and cancer. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high potential of its scientific platform and the significant risks.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Barinthus is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of its vaccine platform trials. The company's chart exists in a world of its own, where data releases are the key events.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Barinthus Biotherapeutics
Barinthus Bio (formerly Vaccitech) is a biotech company developing immunotherapy drugs. Its monthly performance is driven by progress in its clinical programs for the treatment of chronic infections and cancer. Research data is the primary driver of its valuation.
Monthly dynamics of market capitalization of the market segment - Pharma immune
Barinthus Biotherapeutics develops novel T-cell immunotherapies for the treatment of chronic infectious diseases, autoimmune disorders, and cancer. The chart below reflects the overall sentiment in the immunopharma sector, where the company operates at the forefront of science.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Barinthus Biotherapeutics is a biotech company developing immunotherapies for the treatment of chronic diseases and cancer. Its shares are driven by clinical trial results. The company's performance is virtually uncorrelated with the broader market, betting on scientific success.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Barinthus Biotherapeutics
Barinthus Biotherapeutics is a biopharmaceutical company developing immunotherapeutic drugs. Its weekly stock price is a classic example of the biotech sector: sharp and significant fluctuations on news of clinical trial results, data from medical conferences, or regulatory decisions.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Barinthus Biotherapeutics is a biopharmaceutical company developing immunotherapy drugs. Its weekly stock price is a classic example of the biotech sector: sharp and significant fluctuations on news of clinical trial results, data from medical conferences, or regulatory decisions.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Shares of Barinthus, a biotech company, exist in a world of their own, far removed from macroeconomic news. Their performance is driven by clinical trial data. A comparison chart with the S&P 500 clearly demonstrates how the stock can rise or fall, completely ignoring the broader market.
Market capitalization of the company, segment and market as a whole
BRNS - Market capitalization of the company Barinthus Biotherapeutics
The market capitalization chart of Barinthus Biotherapeutics (formerly Vaccitech) tells the story of the scientific platform behind AstraZeneca's COVID-19 vaccine. Its dynamics since the pandemic reflect the company's efforts to apply its technology to the treatment of chronic infectious diseases and cancer. It's a visualization of the search for a "second act" for a successful technology.
BRNS - Share of the company's market capitalization Barinthus Biotherapeutics within the market segment - Pharma immune
Barinthus Biotherapeutics (formerly Vaccitech) is a biopharmaceutical company developing novel immunotherapeutic drugs for the treatment of chronic infections and cancer. Its share of its segment's market capitalization reflects the potential of its scientific platform. The chart below shows how its weighting is influenced by clinical trial results.
Market capitalization of the market segment - Pharma immune
Barinthus Biotherapeutics (formerly Vaccitech) is the company behind the technology used in the AstraZeneca COVID-19 vaccine and is developing immunotherapies for chronic diseases. The chart below shows the overall market capitalization of the immunopharmaceuticals sector, reflecting the potential of platform technologies in the development of new vaccines and drugs.
Market capitalization of all companies included in a broad market index - GURU.Markets
The fight against chronic infections and cancer is shown here. Barinthus Biotherapeutics (formerly Vaccitech, co-developer of the AstraZeneca vaccine) is developing immunotherapies to treat diseases such as hepatitis B. Its line on the graph visualizes the complex path from success in one area to the search for new breakthroughs.
Book value capitalization of the company, segment and market as a whole
BRNS - Book value capitalization of the company Barinthus Biotherapeutics
Barinthus Biotherapeutics (formerly Vaccitech)'s book value is derived from its scientific platforms for developing vaccines and immunotherapies, including the technology underlying the AstraZeneca vaccine. This represents significant intellectual capital. The chart below shows how the company is using its resources to develop new treatments for chronic infections and cancer.
BRNS - Share of the company's book capitalization Barinthus Biotherapeutics within the market segment - Pharma immune
Barinthus Biotherapeutics is a company developing T-cell immunotherapies for the treatment of chronic infections and cancer. Its assets include R&D laboratories and patents. The chart shows the minimal share of physical assets, as its value lies in its scientific platform, not its manufacturing capacity.
Market segment balance sheet capitalization - Pharma immune
Vaccine and immunotherapy development, as the BCap_Seg chart shows, is a knowledge-intensive industry. Barinthus Biotherapeutics operates in this environment, where the primary investment goes into clinical trials rather than plant construction. Its capital is science and data, not physical assets at this stage.
Book value of all companies included in the broad market index - GURU.Markets
Barinthus Biotherapeutics' assets include research laboratories and capital for clinical trials of vaccines against chronic infections and cancer. This book value provides the financial foundation that enables the company to develop potential therapeutics that could transform global medicine.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Barinthus Biotherapeutics
Barinthus Bio (formerly Vaccitech) uses its platform to develop vaccines and immunotherapies. Its value lies in its scientific platform, not its assets. The MvsBCap chart reflects the market's assessment of this technology's potential to combat various diseases, from hepatitis to cancer. Chart volatility will be high, as is typical for all biotechs in the development stage.
Market to book capitalization ratio in a market segment - Pharma immune
Barinthus Biotherapeutics is a biopharmaceutical company developing T-cell immunotherapies. Its valuation is based on the potential of its scientific platform for treating chronic infections and cancer. The chart reflects investors' high appreciation of this scientific potential.
Market to book capitalization ratio for the market as a whole
Barinthus Biotherapeutics develops immunotherapies for the treatment of chronic infectious diseases and cancer. Like many biotech companies, its market value reflects the potential of its scientific platforms. Investors are betting on the future success of clinical trials, as this chart illustrates.
Debts of the company, segment and market as a whole
BRNS - Company debts Barinthus Biotherapeutics
Barinthus Biotherapeutics, a biopharmaceutical company developing vaccines and immunotherapies for chronic diseases and cancer, relies entirely on external funding for its R&D programs. This chart shows how the company manages its resources to advance its drug candidates through the complex and costly stages of clinical trials.
Market segment debts - Pharma immune
Barinthus Biotherapeutics is a biotech company developing T-cell immunotherapy drugs for the treatment of chronic infectious diseases and cancer. R&D funding is its foundation. This chart provides insight into the company's capital structure and its strategy for raising funds for costly clinical trials.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Barinthus Biotherapeutics
Barinthus Biotherapeutics, which develops immunotherapeutic drugs, like many biotech companies, is heavily dependent on external capital. This chart shows its debt load, which is directly related to funding lengthy and expensive clinical trials. The failure of one of its key drugs could make debt servicing impossible.
Market segment debt to market segment book capitalization - Pharma immune
Barinthus Biotherapeutics is a biopharmaceutical company developing immunotherapies for chronic infectious diseases and cancer. This chart shows the company's leverage in the immunology sector. It provides insight into how the company's financial strategy for funding its advanced platforms compares to the risks and development timelines in this field.
Debt to book value of all companies in the market
Barinthus Biotherapeutics is a biopharmaceutical company developing novel T-cell immunotherapies for the treatment of chronic infectious diseases and cancer. The debt-to-equity ratio chart shows the investment climate. For companies reliant on long-term research funding, this metric is an indicator of capital availability.
P/E of the company, segment and market as a whole
P/E - Barinthus Biotherapeutics
This chart of Barinthus Biotherapeutics, a company developing immunotherapy drugs, shows investor expectations for its clinical trials. The trend reflects the belief that its platform will be able to create effective vaccines and drugs for chronic infections and cancer, promising a huge market.
P/E of the market segment - Pharma immune
This chart shows the average P/E for the immunotherapy sector, where Barinthus Biotherapeutics operates. The industry's very high average valuation reflects hopes for new vaccines and drugs. This metric provides context for assessing the market's perception of Barinthus's platform's potential.
P/E of the market as a whole
Barinthus Biotherapeutics develops novel T-cell immunotherapies for the treatment of chronic infectious diseases and cancer. The company uses its platform to create vaccines and therapeutics. This chart shows the market's risk appetite in biotech. It helps understand the market's confidence in the potential of Barinthus's technology platform and how its valuation is responding to clinical trial data.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Barinthus Biotherapeutics
Barinthus Biotherapeutics (formerly Vaccitech) develops immunotherapy drugs for the treatment of chronic infectious diseases and cancer. The company uses the technology behind the AstraZeneca vaccine. This chart shows analyst expectations for the success of its clinical programs and the commercial potential of its platform.
%20P%2FE%20Barinthus%20Biotherapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Barinthus-Biotherapeutics&v=1772513791894 "Chart of the company's future (projected) P/E Barinthus Biotherapeutics")
Future (projected) P/E of the market segment - Pharma immune
Barinthus Biotherapeutics, formerly Vaccitech, develops immunotherapy drugs for chronic infectious diseases, autoimmune disorders, and cancer. This chart shows how its future revenue expectations compare to the industry average. Does the market appreciate the potential of its versatile technology platform?
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772513791933 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Barinthus Biotherapeutics is a biotech company specializing in the development of T-cell immunotherapies for the treatment of chronic diseases and cancer. For companies with future value, this market expectations chart is an indicator of capital availability. When investors are optimistic, Barinthus finds it easier to raise funds for long-term clinical trials.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513791947 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Barinthus Biotherapeutics
Barinthus Biotherapeutics (formerly Vaccitech) uses its platform to develop vaccines and immunotherapies for the treatment of chronic infections and cancer. The company's profitability depends on the success of its clinical programs and partnerships with major pharmaceutical companies. This chart illustrates the balance between high R&D costs and potential revenue from technology licensing.
Profit of companies in the market segment - Pharma immune
Barinthus Biotherapeutics, formerly Vaccitech, uses its platform to develop immunotherapeutic drugs for the treatment of chronic infections, autoimmune diseases, and cancer. This chart shows the overall profitability of the immunotherapy sector, where the ability to "train" the immune system to fight disease is one of the most promising areas in medicine.
Overall market profit
Barinthus Biotherapeutics is a biopharmaceutical company developing immunotherapeutic drugs. Its success depends on scientific breakthroughs, but achieving them requires capital. The overall investment climate, which is closely linked to corporate earnings dynamics in this chart, determines the availability of financing for the biotech sector.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Barinthus Biotherapeutics
Barinthus Biotherapeutics is a biopharmaceutical company developing novel immunotherapeutic drugs for the treatment of chronic infectious diseases and cancer. This chart shows the analyst consensus on the commercial potential of its research portfolio, which is directly dependent on the results of upcoming clinical trials.
%20profit%20of%20the%20company%20Barinthus%20Biotherapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Barinthus-Biotherapeutics&v=1772513791994 "Graph of future (projected) profit of the company Barinthus Biotherapeutics")
Future (predicted) profit of companies in the market segment - Pharma immune
Barinthus Biotherapeutics (formerly Vaccitech) is a biotech company developing the adenovirus vaccine platform that formed the basis of the AstraZeneca COVID-19 vaccine. The company is currently focusing on the treatment of chronic infections and cancer. This chart shows profitability forecasts for the biotech sector, reflecting the expectations of such powerful technology platforms.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772513792023 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
Barinthus Biotherapeutics is a biotech company focused on developing immunotherapeutic drugs for the treatment of chronic diseases. Its market capitalization and funding depend on investor risk appetite. The total return forecast, shown in the chart, forms the overall market backdrop, influencing investor willingness to invest in long-term biotech projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513792081 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Barinthus Biotherapeutics
Barinthus Biotherapeutics is a biotech company developing immunotherapy. For a clinical-stage company, this chart is a measure of hope, not current results. It shows the market value of its scientific platform and the potential for future drugs that could change patients' lives.
P/S market segment - Pharma immune
Barinthus Biotherapeutics, formerly Vaccitech, is a biopharmaceutical company developing immunotherapy drugs for chronic infectious diseases and cancer. This chart shows the average revenue estimate in the biotech sector. It provides an indication of how highly investors value the potential revenue from the company's innovative platform.
P/S of the market as a whole
Barinthus Biotherapeutics, formerly Vaccitech, uses its platform to develop immunotherapeutic drugs for chronic infectious diseases and cancer. Their revenue depends on the success of their clinical programs. This chart provides a general revenue metric that can be used to assess how investors view the potential of their scientific platform.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Barinthus Biotherapeutics
Barinthus Biotherapeutics (formerly Vaccitech) uses its viral vector platform to develop vaccines and immunotherapies against chronic infections and cancer. This chart represents estimates of future revenue from its developments. Success depends on the results of clinical trials and the potential of its platform to generate new drugs.
%20P%2FS%20Barinthus%20Biotherapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Barinthus-Biotherapeutics&v=1772513792185 "The graph of the company's future (projected) P/S Barinthus Biotherapeutics")
Future (projected) P/S of the market segment - Pharma immune
Barinthus Biotherapeutics is a biopharmaceutical company developing novel T-cell-based immunotherapies for the treatment of chronic infectious diseases and cancer. This chart shows how the market views its innovative platform and future sales potential compared to the competitive immunotherapy sector.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772513792233 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
Barinthus Biotherapeutics is a biopharmaceutical company developing T-cell immunotherapies for the treatment of infectious diseases and cancer. This chart, reflecting the overall investment climate, influences its development. Market optimism and investor risk appetite facilitate the company's ability to attract the funding needed to conduct lengthy and expensive clinical trials.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513792288 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Barinthus Biotherapeutics
Barinthus Biotherapeutics, formerly Vaccitech, is a biopharmaceutical company developing novel immunotherapeutics and vaccines for the treatment of chronic infections and cancer. This chart reflects revenue from licensing agreements and collaborations, including royalties from the AstraZeneca vaccine. It demonstrates the financial return on its scientific platform.
Sales of companies in the market segment - Pharma immune
Barinthus Biotherapeutics is a biopharmaceutical company developing novel T-cell immunotherapies for the treatment of chronic infectious diseases, autoimmune disorders, and cancer. Its operations are segmented into various therapeutic programs. This chart shows the financial results of one of these programs, reflecting the progress of its scientific platform.
Overall market sales
Barinthus Biotherapeutics is a biopharmaceutical company developing immunotherapeutic drugs for the treatment of chronic infectious diseases and cancer. Its market capitalization depends on progress in clinical trials. The company is at the forefront of science, and its potential success could lead to new treatment standards, transforming entire segments of healthcare.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Barinthus Biotherapeutics
Barinthus Biotherapeutics (formerly Vaccitech) is a biopharmaceutical company developing new classes of T-cell immunotherapies for the treatment of chronic infectious diseases, autoimmune disorders, and cancer. Its sales forecast reflects the expected success of its broad clinical pipeline.
%20sales%20of%20the%20company%20Barinthus%20Biotherapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Barinthus-Biotherapeutics&v=1772513792547 "Schedule of future (projected) sales of the company Barinthus Biotherapeutics")
Future (projected) sales of companies in the market segment - Pharma immune
Barinthus Biotherapeutics (formerly Vaccitech) develops immunotherapy products for the treatment of chronic infectious diseases and cancer. This chart reflects expectations for the entire immunotherapy sector. It provides insight into the commercial potential analysts predict for new approaches to stimulating the immune system, which is important for assessing the overall industry.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772513792577 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
Barinthus Biotherapeutics develops immunotherapeutic drugs for the treatment of chronic infectious diseases and cancer. Funding for such long-term projects depends on overall market conditions. This sales forecast chart reflects economic confidence, which influences investor risk appetite in the biotech sector.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513792614 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Barinthus Biotherapeutics
Barinthus Biotherapeutics is a biopharmaceutical company developing novel immunotherapeutic drugs for the treatment of chronic infectious diseases and cancer. This chart reflects its financial performance at the clinical stage, where high R&D costs are an investment in the development of future commercially successful drugs.
Market segment marginality - Pharma immune
Barinthus Biotherapeutics is a biotech company developing novel immunotherapeutic drugs for the treatment of chronic infectious diseases and cancer. The effectiveness of their platform lies in its ability to stimulate T-cell immunity. The graph demonstrates how competitive their operating model is in an R&D-intensive industry.
Market marginality as a whole
Barinthus Biotherapeutics is a biopharmaceutical company developing T-cell immunotherapies for the treatment of chronic infectious diseases and cancer. Its success depends on the results of clinical trials. This chart shows average profitability, but for BRNS, breakthroughs in immunology and the potential of its scientific platform are the primary value drivers.
Employees in the company, segment and market as a whole
Number of employees in the company Barinthus Biotherapeutics
Barinthus Biotherapeutics develops immunotherapeutic drugs for the treatment of chronic infections and cancer. This chart shows the growth of its scientific and clinical teams. This increase directly correlates with the progress of its vaccine candidates through clinical trials, which is the main driver of the company's value.
Share of the company's employees Barinthus Biotherapeutics within the market segment - Pharma immune
Barinthus Biotherapeutics (formerly Vaccitech) develops immunotherapeutic drugs for the treatment of chronic infections and cancer. Its scientific platform requires a world-class team. This reflects its standing as an employer in the competitive field of immunology and next-generation vaccine development.
Number of employees in the market segment - Pharma immune
Barinthus Biotherapeutics (formerly Vaccitech) develops immunotherapeutics based on its viral vector platform for the treatment of infectious diseases and cancer. This chart reflects employment in the immunology sector. The growing number of scientists in this field demonstrates widespread recognition of the potential of immunotherapy to address complex medical problems.
Number of employees in the market as a whole
Barinthus Biotherapeutics is a company developing immunotherapeutic drugs. Its staff includes highly qualified scientists. This graph reflects the general labor market, but for Barinthus and similar biotech companies, scientific breakthroughs are key, as they attract investment and allow for the expansion of a team of top specialists.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Barinthus Biotherapeutics (BRNS)
Barinthus Biotherapeutics plc develops T-cell immunotherapy drugs for the treatment of chronic infectious diseases and cancer. This chart shows the company's high market capitalization per employee. This reflects investors' faith in the company's scientific platform, which allows a small team of scientists to create a product worth billions of dollars.
%20of%20the%20company%20Barinthus%20Biotherapeutics%20(BRNS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Barinthus-Biotherapeutics-BRNS&v=1772513793022 "Chart of market capitalization per employee (in thousands of dollars) of the company Barinthus Biotherapeutics (BRNS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Barinthus Biotherapeutics is a biopharmaceutical company developing novel immunotherapeutic drugs for the treatment of chronic infectious diseases and cancer. The company's market value per employee reflects investors' assessment of its scientific potential and clinical research prospects. It demonstrates the value of the team behind breakthrough developments.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772513793094 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Barinthus Biotherapeutics (formerly Vaccitech) is a biotech company that has developed a platform for creating vaccines and immunotherapy drugs (including the technology behind the AstraZeneca vaccine). The chart illustrates the enormous value the market attributes to a scientific platform created by an elite team of researchers.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513793183 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Barinthus Biotherapeutics (BRNS)
Barinthus Biotherapeutics (formerly Vaccitech) is a biotech company that developed a platform for creating T-cell immunotherapies (they created the technology for the AstraZeneca vaccine). They target chronic infections and cancer. This chart shows the intensity of their R&D, measuring how much capital is invested in each scientist to advance their powerful, but not yet profitable, platform.
%20Chart%20Barinthus%20Biotherapeutics%20(BRNS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Barinthus-Biotherapeutics-BRNS&v=1772513793203 "Company Profit Per Employee (in thousands of dollars) Chart Barinthus Biotherapeutics (BRNS)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Barinthus Biotherapeutics is a biotechnology company developing novel T-cell immunotherapies for the treatment of chronic infectious diseases and cancer. Efficiency is determined by the speed and quality of research. This chart shows the financial return on investment for each scientist and employee, allowing one to evaluate their productivity relative to competitors.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772513793274 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Barinthus Biotherapeutics (formerly Vaccitech) is a biotech company developing new immunotherapeutic drugs. They are in the clinical stage, meaning they have no commercial products. This graph, showing negative profit margins, illustrates the "cost" of the research team. It reflects the amount of capital the company invests in each R&D employee to advance the drug.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513793304 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Barinthus Biotherapeutics (BRNS)
Barinthus Biotherapeutics is a biopharmaceutical company developing T-cell immunotherapy drugs for the treatment of chronic diseases and cancer. While in clinical trials, its revenue may be minimal. This timeline will ultimately determine the success of the commercialization of its scientific platform.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Barinthus-Biotherapeutics-BRNS&v=1772513793370 "Sales chart per company employee Barinthus Biotherapeutics (BRNS)")
Sales per employee in the market segment - Pharma immune
Barinthus Biotherapeutics is a biotech company developing novel T-cell immunotherapies for the treatment of chronic infections (hepatitis B) and cancer. This chart compares revenue per employee (from partnerships) to the industry average. It demonstrates how productive their scientific platform is compared to other R&D companies.
Sales per employee for the market as a whole
Barinthus Biotherapeutics (formerly Vaccitech) is a biotech company (a spinoff of Oxford University, which developed the AstraZeneca vaccine) focused on immunotherapy for chronic infections and cancer. Being in the clinical stage, their revenue comes not from sales but from payments from partners (Astellas, J&J). This chart shows the value (revenue) generated by their R&D team.
Short shares by company, segment and market as a whole
Shares shorted by company Barinthus Biotherapeutics (BRNS)
Barinthus Biotherapeutics (formerly Vaccitech) is the biotech company behind the AstraZeneca COVID-19 vaccine technology. They are now focusing on chronic infections and cancer. This chart shows the number of investors who believe the COVID-19 success was a one-off and doubt the success of the company's other developments.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Barinthus-Biotherapeutics-BRNS&v=1772513793549 "Short Shares Chart for the Company Barinthus Biotherapeutics (BRNS)")
Shares shorted by market segment - Pharma immune
Barinthus Biotherapeutics (formerly Vaccitech, the developer of the technology behind the AstraZeneca vaccine) is a biotech company developing T-cell immunotherapies for the treatment of chronic infections (hepatitis B) and cancer. This chart shows bets against the immunotherapy sector, reflecting the high level of investor skepticism regarding the success of clinical trials in this complex field.
Shares shorted by the overall market
Barinthus Bio (BRNS) is a clinical-stage biotech company. Its value is based on future expectations. When this market fear indicator rises, investors' risk appetite evaporates. They are the first to sell speculative, loss-making biotechs like BRNS in favor of safer assets.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Barinthus Biotherapeutics (BRNS)
Barinthus Biotherapeutics (formerly Vaccitech) uses its platform to develop immunotherapies for chronic infections and cancer. It's a biotech that requires patience. This indicator shows when trial news (above 70) triggers a surge in optimism, or when development delays (below 30) lead to selloffs.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Barinthus-Biotherapeutics-BRNS&v=1772513793678 "RSI 14 indicator chart for the company's stock Barinthus Biotherapeutics (BRNS)")
RSI 14 Market Segment - Pharma immune
Barinthus Biotherapeutics (formerly Vaccitech) is a biotech company using its viral vector platform to develop vaccines against infectious diseases (hepatitis B) and cancer. This chart measures the overall momentum in the immunological biotech sector. It helps determine whether the entire segment is oversold.
RSI 14 for the overall market
For Barinthus Bio, a biotech company in R&D, this chart is a lifeline showing capital availability. During periods of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is shut off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast BRNS (Barinthus Biotherapeutics)
Barinthus Biotherapeutics (formerly Vaccitech) is the biotech company that developed the viral platform (ChAdOx) that underlies the AstraZeneca COVID-19 vaccine. They are currently using it to treat cancer and hepatitis B. This chart shows the analysts' average 12-month forecast, reflecting their bet on the potential of this R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-BRNS-Barinthus-Biotherapeutics&v=1772513793920 "A chart showing analyst consensus forecasts for the expected stock price. BRNS (Barinthus Biotherapeutics)")
The difference between the consensus estimate and the actual stock price BRNS (Barinthus Biotherapeutics)
Barinthus Bio (formerly Vaccitech) is a biotech company that developed the ChAdOx platform that formed the basis of the AstraZeneca COVID-19 vaccine. It is currently focusing on hepatitis B and cancer treatments. This chart measures the gap between the current price and the consensus target price. It shows how confident experts are in their R&D pipeline.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-BRNS-Barinthus-Biotherapeutics&v=1772513793943 "A chart showing the difference between the consensus forecast and the actual stock price. BRNS (Barinthus Biotherapeutics)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Barinthus (formerly Vaccitech) is a biotech company that "trains" T cells (the immune system) to attack not only cancer but also chronic infections such as hepatitis B. This chart shows analysts' overall expectations for the entire immune pharma sector. It reflects whether experts believe breakthroughs in the treatment of chronic viral diseases are possible.
Analysts' consensus forecast for the overall market share price
Barinthus Biotherapeutics (formerly Vaccitech) is a biotech company (spun out of Oxford) that has developed a platform (ChAdOx) for creating vaccines (including the AstraZeneca vaccine) and immunotherapies. This chart shows the overall risk appetite. For Barinthus, a company with a proven but risky platform, overall market optimism is important for funding their new oncology projects.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Barinthus Biotherapeutics
Barinthus Biotherapeutics (formerly Vaccitech) is a biotech company (formerly an Oxford spinout) that helped create the AstraZeneca vaccine. Their R&D platform (ChAdOx) is used to develop vaccines against chronic infections (Hepatitis B), autoimmune diseases, and cancer. This chart is a summary of their post-COVID R&D platform, reflecting their progress in clinical trials.
AKIMA Market Segment Index - Pharma immune
Barinthus Biotherapeutics (BRNS), formerly Vaccitech, is the biotech company behind the development of the AstraZeneca COVID-19 vaccine. They are currently using their platforms (ChAdOx, MVA) to treat chronic infections and cancer. The chart shows the segment average, helping investors assess how this powerful scientific platform compares to the average in the immune pharma sector.
The AKIM Index for the overall market
Barinthus Biotherapeutics (formerly Vaccitech) is a biotech company developing immunotherapies for the treatment of chronic infections (hepatitis B) and autoimmune diseases. This chart, which reflects the market average, provides a macro backdrop. It helps assess how BRNS, with its roots in Oxford science, compares to overall economic trends.
